摘要
目的探讨多奈哌齐联合尼莫地平治疗血管性认知障碍(非痴呆型)的疗效及安全性。方法将62例血管性认知障碍(非痴呆型)的患者随机分为两组,对照组给予常规抗血小板聚集、调脂、控制血压、控制血糖、改善循环治疗,观察组在对照组治疗的基础上加用多奈哌齐、尼莫地平治疗,治疗前及治疗后10周均应用MMSE、ADL、HDS对患者进行评分从而进行评价。结果治疗10周后观察组的MMSE、ADL、HDS得分较本组治疗前有明显提高,且较对照组改善显著,P<0.05,差异有统计学意义;两组均无明显不良反应。结论多奈哌齐联合尼莫地平治疗血管性认知障碍(非痴呆型)是目前相对有效的药物,且临床使用比较安全。
Objective To explore efficacy and safety treatment to vascular cognitive impairment （non-de- mented） with donepezil and nimodipine. Methods 62 cases of vascular cognitive impairment （non-dement- ed） patients were randomly divided into two groups; conventional anti-platelet aggregation, lipid adjust- ment, blood pressure control, blood sugar control and circular treatment improvement were done to the con- trol group. Compared with control group, donepezil and nimodipine treatment were added to treatment group. MMSE, ADL and HDS were used to scorel0 weeks before and after treatment for evaluation. Results After 10 weeks of treatment, MMSE, ADL, HDS score of treatment group were significantly improved com- pared with this group before and after treatment. Significant improvement was seen that the control group （P〈0.05） was statistically significant and no significant untoward reactions was observed from the two groups. Conclusion Donepezil combined with nimodipine was proved as relatively effective and also ob- served clinically safer in the treatment of vascular cognitive impairment （non-demented）.
出处
《中国城乡企业卫生》
2013年第4期36-37,共2页
Chinese Journal of Urban and Rural Enterprise Hygiene
